For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
84 locally advanced, nonmetastatic head/neck or esophageal squamous-cell-carcinoma patients, 221 chemotherapy cycles; 83 evaluable after one early death.
Reported findings. No significant hematologic protection demonstrated in this randomized blinded placebo trial.
Nonresponse. No statistically significant difference in hematologic nadirs or toxicity duration was detected during carboplatin/fluorouracil co-treatment.
Harms. Anemia and lymphopenia were more frequent with goralatide despite favorable author tolerability wording. One early death occurred before evaluation; treatment attribution is unspecified.
Limits. Chemotherapy cycles are not independent patients. Favorable author tolerability language must remain alongside the reported hematologic harms. This preparation does not establish benefit or safety for an unspecified commercial fragment or other indication.
Preparation: Experimental goralatide; catalog SDKP/Ac-SDKP acetylation and preparation equivalence unverified. Route: Peptide route unspecified in abstract; fluorouracil intravenous administration does not establish goralatide route.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Identity context
Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.
Source identity support only; not an additional human trial cohort.
Reported findings. Supports the goralatide/AcSDKP name relationship, not efficacy of the catalog fragment.
Nonresponse. This identity record provides no population response-rate or trial-effect estimate.
Harms. Identity correspondence is not evidence of clinical safety.
Limits. This source is separate from the randomized human trial PMID8535033 and is not counted as independent trial efficacy evidence. Unacetylated SDKP and an unspecified supplier preparation are not silently equated to AcSDKP.
Preparation: Original paper names goralatide as AcSDKP; catalog fragment acetylation, chemistry and equivalence remain unverified. Route: No route inferred from this identity-support record.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism.
Normal human bone-marrow-derived primitive progenitors in adherent layers of long-term cultures; not treated patients.
Reported findings. No benefits established in the inspected original abstract; absence of reporting does not establish absence of an effect.
Nonresponse. Unacetylated SDKP did not inhibit proliferation of primitive normal progenitors in long-term-culture adherent layers in the tested comparator condition.
Harms. No harms established in the inspected original abstract; absence of reporting does not establish safety.
Limits. Single specified cultured-cell endpoint; no human clinical efficacy, exposure outcomes or safety established. Parent AcSDKP lowered S-phase cycling and affected colony formation in separate arms. These acetylated-compound results must not be assigned to unacetylated SDKP. Full methods, comparator end groups, purity and preparation provenance are not established from the accessible original abstract. Original publisher PDF unavailable. Original indexed abstract and raw metadata were reconciled; original article full-response hash remains null. No indexed correction/retraction link was returned in the fresh metadata; this is a bounded lifecycle check only. No SDKP-specific harms are established from the accessible abstract; not evidence of safety.
Preparation: Unacetylated SDKP comparator explicitly tested in original abstract, separately from NAc-Ser-Asp-Lys-Pro-OH (AcSDKP). SDKP end-group/purity details not established from abstract. Route: Added to long-term cell culture; no human administration route.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.